Phaseline

Targets › HSV-TK

HSV-TK: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2030.

Open in Phaseline: the race on HSV-TK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Methodist Hospital Research InstituteHSV-Tk
Herpes simplex virus thymidine kinase gene therapy delivered by adenoviral vector to enhan
HSV-TKPhase 2High-risk Prostate Cancer–
TrogenixTGX-007
AAV-mediated dual-payload gene therapy delivering HSV-tk and IL-12 for tumor cell killing
HSV-TK, IL12Phase 1Glioblastoma (GBM)Mar 2030

Conditions

High-risk Prostate Cancer (1) Glioblastoma (GBM) (1)

Modalities

mixed (1), small molecule (1)

Companies

The Methodist Hospital Research Institute (1) Trogenix (1)

Related targets

IL12 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.